Does the media favor ALUR or NEPH?

In the previous week, Allurion Technologies had 3 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Allurion Technologies and 1 mentions for Nephros. Nephros' average media sentiment score of 0.03 beat Allurion Technologies' score of -0.18 indicating that Nephros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PSTV or ALUR?

In the previous week, Allurion Technologies had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Allurion Technologies and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALUR or NSPR?

In the previous week, Allurion Technologies had 2 more articles in the media than InspireMD. MarketBeat recorded 4 mentions for Allurion Technologies and 2 mentions for InspireMD. InspireMD's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that InspireMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PETV or ALUR?

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Allurion Technologies (ALUR) Competitors

$0.58 0.00 (0.00%)

As of 06/17/2026

Compare

ALUR vs. NEPH, PSTV, NSPR, PETV, and MLSS

Should you buy Allurion Technologies stock or one of its competitors? MarketBeat compares Allurion Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allurion Technologies include Nephros (NEPH), Plus Therapeutics (PSTV), InspireMD (NSPR), PetVivo (PETV), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry.

How does Allurion Technologies compare to Nephros?

Allurion Technologies (NYSE:ALUR) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Allurion Technologies currently has a consensus target price of $45.00, suggesting a potential upside of 7,658.62%. Nephros has a consensus target price of $6.00, suggesting a potential upside of 81.82%. Given Allurion Technologies' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Allurion Technologies has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

In the previous week, Allurion Technologies had 3 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Allurion Technologies and 1 mentions for Nephros. Nephros' average media sentiment score of 0.03 beat Allurion Technologies' score of -0.18 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros has higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Nephros	$19.12M	1.87	$1.19M	$0.07	47.14

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nephros has a net margin of 4.06% compared to Allurion Technologies' net margin of -199.96%. Nephros' return on equity of 7.66% beat Allurion Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Nephros	4.06%	7.66%	5.86%

Summary

Nephros beats Allurion Technologies on 12 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Plus Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

In the previous week, Allurion Technologies had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Allurion Technologies and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics presently has a consensus target price of $56.40, suggesting a potential upside of 1,282.35%. Allurion Technologies has a consensus target price of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Plus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allurion Technologies has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.39	-$22.39M	-$2.30	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

Allurion Technologies has a net margin of -199.96% compared to Plus Therapeutics' net margin of -230.24%. Allurion Technologies' return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Allurion Technologies	-199.96%	N/A	-77.13%

Summary

Allurion Technologies beats Plus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to InspireMD?

Allurion Technologies (NYSE:ALUR) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Allurion Technologies had 2 more articles in the media than InspireMD. MarketBeat recorded 4 mentions for Allurion Technologies and 2 mentions for InspireMD. InspireMD's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that InspireMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allurion Technologies has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 34.1% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Allurion Technologies has a net margin of -199.96% compared to InspireMD's net margin of -413.96%. Allurion Technologies' return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
InspireMD	-413.96%	-69.42%	-57.68%

Allurion Technologies has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
InspireMD	$10.85M	3.03	-$19.92M	-$0.73	N/A

Allurion Technologies presently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. InspireMD has a consensus price target of $4.50, indicating a potential upside of 541.94%. Given Allurion Technologies' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

InspireMD beats Allurion Technologies on 9 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to PetVivo?

PetVivo (NASDAQ:PETV) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Allurion Technologies has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	28.73	-$10.95M	-$0.38	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

Allurion Technologies has a net margin of -199.96% compared to PetVivo's net margin of -902.82%. Allurion Technologies' return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Allurion Technologies	-199.96%	N/A	-77.13%

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

24.5% of PetVivo shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PetVivo has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

In the previous week, Allurion Technologies had 4 more articles in the media than PetVivo. MarketBeat recorded 4 mentions for Allurion Technologies and 0 mentions for PetVivo. PetVivo's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that PetVivo is being referred to more favorably in the media.

Company	Overall Sentiment
PetVivo	Neutral
Allurion Technologies	Neutral

Summary

Allurion Technologies beats PetVivo on 10 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to Milestone Scientific?

Allurion Technologies (NYSE:ALUR) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by company insiders. Comparatively, 12.5% of Milestone Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Allurion Technologies had 4 more articles in the media than Milestone Scientific. MarketBeat recorded 4 mentions for Allurion Technologies and 0 mentions for Milestone Scientific. Milestone Scientific's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that Milestone Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
Allurion Technologies	Neutral
Milestone Scientific	Neutral

Milestone Scientific has lower revenue, but higher earnings than Allurion Technologies. Milestone Scientific is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Milestone Scientific	$8.90M	2.96	-$6.93M	-$0.05	N/A

Milestone Scientific has a net margin of -52.01% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Milestone Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Milestone Scientific	-52.01%	-60.26%	-40.23%

Allurion Technologies has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Allurion Technologies presently has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Milestone Scientific has a consensus price target of $1.00, suggesting a potential upside of 235.35%. Given Allurion Technologies' higher possible upside, equities research analysts clearly believe Allurion Technologies is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Milestone Scientific beats Allurion Technologies on 9 of the 15 factors compared between the two stocks.

Get Allurion Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALUR vs. The Competition

Export

Metric	Allurion Technologies	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$8.70M	$8.08B	$6.44B	$23.25B
Dividend Yield	N/A	2.59%	2.69%	4.07%
P/E Ratio	-0.05	15.24	24.67	31.08
Price / Sales	0.51	6.99	528.41	105.78
Price / Cash	N/A	16.83	44.82	24.45
Price / Book	-0.02	3.21	10.76	4.64
Net Income	-$7.20M	$226.25M	$3.56B	$1.07B
7 Day Performance	-93.33%	-1.89%	1.03%	0.15%
1 Month Performance	-95.34%	-3.72%	0.45%	0.18%
1 Year Performance	-98.41%	-1.12%	29.69%	23.21%

Allurion Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALUR Allurion Technologies	1.4798 of 5 stars	$0.58 flat	$45.00 +7,658.6%	-98.4%	$8.70M	$17.21M	N/A	501
NEPH Nephros	2.1317 of 5 stars	$3.19 +1.9%	$6.00 +88.1%	-23.1%	$33.98M	$18.79M	45.58	30	Positive News High Trading Volume
PSTV Plus Therapeutics	1.8103 of 5 stars	$4.57 -5.8%	$56.40 +1,134.1%	-11.4%	$33.39M	$5.21M	N/A	20
NSPR InspireMD	4.0799 of 5 stars	$0.71 -6.3%	$4.50 +531.7%	-72.2%	$33.37M	$10.85M	N/A	50	Gap Up
PETV PetVivo	N/A	$0.85 +6.3%	N/A	+3.1%	$30.96M	$1.05M	N/A	20	Upcoming Earnings Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ALUR) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allurion Technologies (ALUR) Competitors

ALUR vs. NEPH, PSTV, NSPR, PETV, and MLSS

How does Allurion Technologies compare to Nephros?

Summary

How does Allurion Technologies compare to Plus Therapeutics?

Summary

How does Allurion Technologies compare to InspireMD?

Summary

How does Allurion Technologies compare to PetVivo?

Summary

How does Allurion Technologies compare to Milestone Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allurion Technologies (ALUR) Competitors

ALUR vs. NEPH, PSTV, NSPR, PETV, and MLSS

How does Allurion Technologies compare to Nephros?

Do analysts prefer ALUR or NEPH?

Which has more volatility and risk, ALUR or NEPH?

Does the media favor ALUR or NEPH?

Which has higher valuation and earnings, ALUR or NEPH?

Do insiders & institutionals have more ownership in ALUR or NEPH?

Is ALUR or NEPH more profitable?

Summary

How does Allurion Technologies compare to Plus Therapeutics?

Do insiders and institutionals hold more shares of PSTV or ALUR?

Which has more risk & volatility, PSTV or ALUR?

Does the media prefer PSTV or ALUR?

Do analysts rate PSTV or ALUR?

Which has preferable earnings & valuation, PSTV or ALUR?

Is PSTV or ALUR more profitable?

Summary

How does Allurion Technologies compare to InspireMD?

Does the media favor ALUR or NSPR?

Which has more risk & volatility, ALUR or NSPR?

Do insiders & institutionals have more ownership in ALUR or NSPR?

Is ALUR or NSPR more profitable?

Which has higher earnings and valuation, ALUR or NSPR?

Do analysts prefer ALUR or NSPR?

Summary

How does Allurion Technologies compare to PetVivo?

Which has stronger earnings & valuation, PETV or ALUR?

Is PETV or ALUR more profitable?

Do analysts recommend PETV or ALUR?

Do insiders and institutionals believe in PETV or ALUR?

Which has more risk & volatility, PETV or ALUR?

Does the media refer more to PETV or ALUR?

Summary

How does Allurion Technologies compare to Milestone Scientific?

Do insiders and institutionals hold more shares of ALUR or MLSS?

Does the media favor ALUR or MLSS?

Which has better valuation & earnings, ALUR or MLSS?

Is ALUR or MLSS more profitable?

Which has more volatility and risk, ALUR or MLSS?

Do analysts recommend ALUR or MLSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools